Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an array of conditions.

By Jonathan Gardner • Updated Jan. 8, 2026

CDC, following Trump’s orders, weakens US stance on childhood vaccinations

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots going forward, down from 17.

By Delilah Alvarado • Updated Jan. 6, 2026

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Surfing the AI wave: How pharma can harness agents in ERP

AI is reshaping pharma faster than any tech wave before. Learn where to start and how to scale.

By Thomas Van Dorpe • Jan. 5, 2026

Novo Nordisk’s weight loss pill approved by FDA

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market. 

By Jonathan Gardner • Dec. 23, 2025

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 23, 2025

Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

By Kristin Jensen • Dec. 22, 2025

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

By BioPharma Dive staff • Dec. 19, 2025

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity. 

By Jonathan Gardner • Dec. 18, 2025

FDA clears GSK’s twice-yearly asthma drug

Exdensur is now the first asthma biologic to be approved for twice-yearly dosing, and could potentially change standard of care for those with severe disease.

By Delilah Alvarado • Updated Dec. 17, 2025

Sanofi MS drug hits two setbacks

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the disease.

By Jacob Bell • Dec. 15, 2025

Novartis notches another win for drug acquired in MorphoSys deal

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low platelet counts.

By Jonathan Gardner • Dec. 9, 2025

Pfizer dips into China for another try at an obesity pill

A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.

By Kristin Jensen • Dec. 9, 2025

FDA raises CAR-T approval standards; Novartis bets on an AI startup

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol Myers Squibb and BioNTech proved effective in breast cancer patients.

By BioPharma Dive staff • Dec. 9, 2025

J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

By Jonathan Gardner • Dec. 9, 2025

How digital companion apps unlock value across the drug lifecycle

Where companion apps unlock value across the full drug lifecycle, from Pre-Rx to Post-Rx.

Dec. 8, 2025

At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care. 

By Jonathan Gardner • Dec. 7, 2025

After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

By Jacob Bell • Dec. 3, 2025

Specialty pharmacy’s secret weapon: The unsung power of the enrollment form

One form can make or break orphan drug success and patient outcomes.

Dec. 1, 2025

Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3

The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

By BioPharma Dive staff • Nov. 26, 2025

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

By Jonathan Gardner • Nov. 26, 2025

Novartis wins approval to use SMA gene therapy in older patients

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor function.

By Jonathan Gardner • Nov. 25, 2025

How do Big Pharma employees rate their CEOs?

Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.

By Alexandra Pecci • Nov. 25, 2025

Bayer’s experimental blood-thinner notches trial win in stroke prevention

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

By Jonathan Gardner • Nov. 24, 2025

Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies

The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.

By Jacob Bell • Nov. 24, 2025

FDA probes effects of Takeda rare disease drug after patient death

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

By Kristin Jensen • Nov. 24, 2025